Leap Therapeutics LPTX shares are trading higher after the company announced it presented updated results for its DKN-01 plus tislelizumab which showed "compelling" activity in first-line patients with gastric, gastroesophageal junction cancer.
Leap Therapeutics' stock is trading up 38.86% to a price of $2.68. Thursday the stock has been traded at a volume of 95.85 million, about 2974.69% of its recent 30-day volume average of 3.22 million.
The moving average price of the stock over the past 50 days was $1.59 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $3.24 and as low as $1.33.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
